These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36895314)

  • 1. Leuprolide Acetate and QTc Interval in Gender-Diverse Youth.
    Waldner RC; Doulla M; Atallah J; Rathwell S; Grimbly C
    Transgend Health; 2023 Feb; 8(1):84-88. PubMed ID: 36895314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron.
    Eitel KB; Hodax JK; DiVall S; Kidd KM; Salehi P; Sequeira GM
    J Adolesc Health; 2023 Feb; 72(2):307-311. PubMed ID: 36404242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT.
    Abbasi D; Faiek S; Shetty S; Khan E
    Cureus; 2020 Jul; 12(7):e9041. PubMed ID: 32782861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgender Youth Referred to Clinics for Gender-Affirming Medical Care in Canada.
    Bauer GR; Pacaud D; Couch R; Metzger DL; Gale L; Gotovac S; Mokashi A; Feder S; Raiche J; Speechley KN; Temple Newhook J; Ghosh S; Sansfaçon AP; Susset F; Lawson ML;
    Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34620727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and outcomes of long QTc in acute medical admissions.
    Mahmud R; Gray A; Nabeebaccus A; Whyte MB
    Int J Clin Pract; 2018 Nov; 72(11):e13250. PubMed ID: 30222237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.
    Ibáñez L; Potau N; Zampolli M; Virdis R; Gussinyé M; Carrascosa A; Saenger P; Vicens-Calvet E
    J Clin Endocrinol Metab; 1994 Jan; 78(1):30-5. PubMed ID: 7507123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrected QT Interval Prolongation in Pediatric and Young Adult Patients on Methadone for Cancer-Related Pain.
    Madden K; Jo E; Williams JL; Liu D; Bruera E
    J Pain Symptom Manage; 2019 Oct; 58(4):678-684. PubMed ID: 31195079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic Findings in Children Treated with Leuprolide Acetate for Precocious Puberty: Does it Cause Prolonged QT?
    Altun EE; Yaşar A; Dursun F; Seymen G; Kırmızıbekmez H
    J Clin Res Pediatr Endocrinol; 2024 Jun; ():. PubMed ID: 38828891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial Characteristics of Transgender Youth Seeking Gender-Affirming Medical Treatment: Baseline Findings From the Trans Youth Care Study.
    Chen D; Abrams M; Clark L; Ehrensaft D; Tishelman AC; Chan YM; Garofalo R; Olson-Kennedy J; Rosenthal SM; Hidalgo MA
    J Adolesc Health; 2021 Jun; 68(6):1104-1111. PubMed ID: 32839079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Children and adolescents in the Amsterdam Cohort of Gender Dysphoria: trends in diagnostic- and treatment trajectories during the first 20 years of the Dutch Protocol.
    van der Loos MATC; Klink DT; Hannema SE; Bruinsma S; Steensma TD; Kreukels BPC; Cohen-Kettenis PT; de Vries ALC; den Heijer M; Wiepjes CM
    J Sex Med; 2023 Feb; 20(3):398-409. PubMed ID: 36763938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
    Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
    Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgender Dependent Adolescents in the U.S. Military Health Care System: Demographics, Treatments Sought, and Health Care Service Utilization.
    Van Donge N; Schvey NA; Roberts TA; Klein DA
    Mil Med; 2019 May; 184(5-6):e447-e454. PubMed ID: 30325452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty.
    Mul D; de Muinck Keizer-Schrama SM; Oostdijk W; Drop SL
    Horm Res; 1999 Dec; 51(6):270-6. PubMed ID: 10640887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.